The FUSION data is a major de-risking event for Heartflow's clinical and commercial trajectory, providing the highest-grade evidence for routine FFRCT use after CCTA. Traders should watch for accelerated guideline updates (ESC/ACC/AHA), expanded reimbursement decisions, and potential partnership or acquisition interest given the now-validated clinical utility at a critical decision node.
Price Chart
Executive Summary
Heartflow announced late-breaking one-year results from the independent, government-funded FUSION trial at ESC Congress 2026, showing that adding its FFRCT Analysis to standard CCTA scans reduced unnecessary invasive heart procedures by 44% (p<0.001) with no difference in safety or revascularization rates. The study, published simultaneously in JACC, provides robust, unbiased evidence supporting routine clinical integration of Heartflow's AI platform at a critical decision point after CCTA identifies obstructive stenosis.
Key Facts
- FUSION trial (n=528) showed a sustained 44% relative reduction in unnecessary invasive coronary angiography (ICA) at one year in the Heartflow pathway vs. CCTA-only (22% vs 39%; p<0.001).
- Overall ICA rates were significantly lower at one year (43% Heartflow vs 61% CCTA alone; p<0.001).
- Revascularization rates were identical (20% vs 20%; p=0.948), proving no under-treatment.
- No significant differences in safety endpoints (MACE, ICA complications, stroke).
- FUSION is an independent, government-funded trial with no industry involvement in design or analysis.
- Results published simultaneously in the Journal of the American College of Cardiology (JACC).
- Heartflow technology is adopted by >1,800 institutions globally, with >625 peer-reviewed publications and >750,000 patients treated.
Financial Impact
Positive catalyst for adoption and reimbursement — FUSION provides Level 1 evidence at a pivotal clinical decision point, likely accelerating guideline inclusion and commercial uptake. No specific revenue or deal value stated.
Risk Factors
- Competitive CT-FFR technologies (e.g., from Canon, Siemens) may also seek similar evidence.
- Reimbursement and guideline adoption timelines are uncertain and may take quarters to materialize.
- Stock at $4.3B market cap with 87% analyst bullishness — positive expectations may already be partially priced in.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352507 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 144 | $55.43 | awaiting T+5 | — | $57.01 (+2.84%) |
Oct 22, 2026 4d ago | 144 | $55.43 | awaiting T+5 | — | $57.01 (−2.84%) |
Oct 19, 2026 7d ago | Press Release | $55.59 | awaiting T+5 | — | $57.01 (+2.55%) |
Sep 21, 2026 5w ago | Insider Cluster | $50.17 $49.83 | ▲ +0.68% | ▼ −0.51% | $57.01 (−13.62%) |
Sep 18, 2026 5w ago | Insider Cluster | $50.33 $49.92 | ▲ +0.81% | ▼ −0.21% | $57.01 (−13.26%) |
Sep 15, 2026 5w ago | Insider Cluster | $48.30 $47.39 | ▼ −1.88% | ▼ −4.45% | $57.01 (+18.02%) |
Sep 14, 2026 6w ago | Insider Cluster | $48.33 $50.17 | ▼ −3.81% | ▼ −1.68% | $57.01 (−17.95%) |
Aug 28, 2026 8w ago | Press Release | $47.78 $48.91 | ▲ +2.37% | ▲ +2.26% | $57.01 (+19.31%) |
Aug 25, 2026 8w ago | Insider Cluster | $48.94 $50.00 | ▲ +2.17% | ▲ +2.29% | $57.01 (+16.48%) |
Aug 20, 2026 9w ago | Insider Cluster | $49.75 $47.78 | ▼ −3.96% | ▼ −4.43% | $57.01 (+14.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers